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Abstract 
The clinical form of canine juvenile generalized demodicosis is usually related genetically with immune deficiency. In this regard, in 
the current study we have evaluated the impact of immunostimulant agent as ascorbic acid (AA) on the rapid recovery of dogs 
naturally affected by generalized demodicosis. To achieve this purpose, twenty- eight German Shepherd male dogs were used in 
this study and divided randomly into two groups, then received daily oral dose of ivermectin (IVR) 1% (0.5 mg kg
-1
) alone and IVR 
1% in combination with AA (500 mg per animal, twice daily) for two months, respectively. Total mite numbers, egg counts, 
eosinophil counts and skin lesion score were used for assessment the treatment efficacy after 30, 60, 90, and 120 days subsequent 
to the initial treatment. Seventeen dogs (IVR (n = 8), and IVR + AA (n = 9)) completed the full length of experiment (4- months) as 
11 dogs were withdrawn due to various causes. Out of 17 dogs completing the 4 months trial, two dogs treated with IVR + AA 
combination therapy achieved the parasitological cure. The results revealed rapid and marked reduction in the total mite numbers 
and eosinophil counts treated with combination therapy in comparison with those administrated ivermectin alone. These findings 
exhibited the potential anti-Demodex effect of ivermectin when administrated in combination with immunostimulant agent and 
highlight the impact of an inexpensive, available and immunomodulatory agent as ascorbic acid in treatment of canine juvenile 
generalized demodicosis.  
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INTRODUCTION 
Canine juvenile generalized demodicosis (CanJGD) is 
an inflammatory skin disease caused by infestation of the 
normal hair follicle by mite Demodex canis, and in some 
cases, Demodex injai (Desch and Hillier, 2003; Ordeix et 
al., 2009). The disease characterized by high prevalence in 
purebred young dogs and is considered a hereditary skin 
disease (Ravera et al., 2015). The mechanism of CanJGD 
inheritance and genetic defect(s) associated with it, is still 
unknown (Wilkie, 1979; Ravera et al., 2015). However, the 
key role in its pathogenesis is relied on the body immune 
system (Hirsh et al., 1975; Ravera et al., 2015; Beugnet et 
al., 2016).  
Two clinical forms are identified for canine 
demodicosis; localized and generalized ones as well as 
juvenile and adult onset (Ravera et al., 2015). Presence of 
patches of alopecia with mild erythema in young dogs and 
lesions number less than four with a diameter of up to 2.5 
cm is characteristic to the localized form and this form is 
regressed spontaneously without treatment (Guaguère and 
Beugnet, 2008; Mueller et al., 2009 & 2012). Whereas, the 
generalized form of demodicosis is usually more severe 
than the localized one and may be complicated with 
secondary bacterial infection leading to death (Mueller et 
al., 2012). Generalized demodicosis may develop from the 
localized condition or occur spontaneously in young and 
sub-adult dogs, but also recorded in older animals 
especially those under severe stress or with underlying 
diseases (Guaguère and Beugnet, 2008). The most 
frequent form in the field is the generalized one, which is 
characterized by presence of five or more affected areas 
(erythema, follicular papules to pustules, hair loss, and 
scales) in the body, and/or pododemodicosis involving two 
or more paws (Beugnet et al., 2016). CanJGD is a 
thwarting disease that requires aggressive medical 
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intervention with miticidal and supportive therapy (Paterson 
et al., 2014). Although some cases self-curing particularly 
in young animals (Paterson et al., 2009). In general, the 
course of CanJGD is unexpected as it is a potentially 
serious disease and many affected dogs are euthanized 
due to the severity of their disaster and their owner’s 
frustration in managing the disease (Paterson et al., 2009). 
The unpredictable course of the disease and the 
inheritance property of the disease with its main relation to 
the body immune status, makes the administration of 
immunostimulant agents to the diseased animals with 
studying their clinical response has a great priority in 
treatment of such clinical cases. In this concern, ascorbic 
acid (AA) is an essential water-soluble nutrient present in 
the extracellular fluid and the cytosolic compartment of the 
cell, which primarily exerts its effect on host defense 
mechanisms and immune homeostasis (Jacob and Burri, 
1996). The potential immunostimulant effect of ascorbic 
acid causes enhancement of T-lymphocyte proliferation 
and inhibition of T- cell apoptosis signaling pathways in 
response to infection (Naidu, 2003). Moreover, previous 
study has reported the impact of ascorbic acid in collagen 
synthesis and modification (Dhama et al., 2015). 
Furthermore, the preventative and therapeutic success of 
ascorbic acid in treatment of scurvy, viral infections, and 
common cold (Bowie and O’Neill, 2000); and the 
antioxidant effects of vitamin C on cancer (Mantovani et al., 
2003) and euglycemic- induced pateinets (Carroll and 
Schade, 2003) in various experimental studies were 
reported. In fact, ascorbic acid is produced normally in the 
animal body through L-gulconolactone oxidase enzyme 
(Fahey & Westmoreland, 2012). However, the efficacy of 
additional administration of ascorbic acid on the rapid 
recovery of dogs suffered from juvenile generalized 
demodicosis did not evaluated yet. Therefore, in this study 
we investigated the potential of ascorbic acid on the 
recovery of dogs naturally affected by generalized 
demodicosis with juvenile onset. To the best of author’s 
knowledge, this is the first study explores the effect of such 
inexpensive and easily available immunostimulant agent on 
the recovery of immunodeficiency related disease; canine 
juvenile generalized demodicosis under natural field 
condition. 
  
MATERIALS AND METHODS 
Ethical approval  
All applicable international, national, and/or institutional 
guidelines for the care and use of animals were followed. 
 
Animals and Clinical examination 
Twenty- eight German Shepherd dogs were included 
in this study after diagnosed with CanJGD. Diseased dogs 
were selected for this study according to the inclusion 
criteria; a minimum of five affected areas (>10 cm2 each), a 
single-affected body region (>100 cm2) or two or more 
affected paws (Gortel, 2006). Detection of D. canis mites in 
scrapings and/or hair plucking samples collected from 
lesional skin was used for the diagnosis the infection. 
Presence of multi-focal areas of alopecia accompanied by 
fine scales on the face, pre-ocular area, commissures of 
the lips and the forelegs, erythema, follicular casts, scales 
and crusts indicate the presence of demodicosis (Radostits 
et al., 2007). All dogs were belonged to private owners and 
all owners are signed owner permission for annexation 
their dogs in the study. The Dog’s ages were ranged from 
10 - 14 months old and their body weights were ranged 
from 18-26 kg. Ten blood sample were collected from 
apparently healthy German Shepherd dogs that were 
admitted either to the Veterinary Teaching Hospital, Faculty 
of Veterinary Medicine, Mansoura University, Mansoura, 
Egypt or to private clinics for regular health-check, 
vaccination, regular de-worming or pre-neutering check-up. 
Sampling process was performed after obtaining written 
permission from the owners and get confirmation that these 
healthy dogs had no a previous history of sarcoptic mange 
or cutaneous hypersensitivity. The age of healthy dogs was 
ranged from 8-14 months. 
 
Treatment protocol and efficacy assessment 
The diseased animals under study were allocated into 
two groups each group contain 14- animals using a 
computer-generated randomization schedule. First group 
received daily treatment by (IVR) 1% orally (Merck AGVET, 
Pointe-Claire, Québec, Canada) at a dose of 0.5 mg kg
-1
. 
The drug was administrated for continuous two months. 
While, combination therapy from ivermectin 1% (Merck 
AGVET) and ascorbic acid (iHerb.com) (IVR + AA) was 
administrated to the second group in the same inoculation 
period. Ascorbic acid was administered twice time per day 
orally at a dose of 500 mg per animal
 
in the diet (Schwartz, 
1996) for two months. A gradual increase in the dose rate 
of ivermectin was applied in order to recognize dog’s 
sensitivity to ivermectin before reaching to the critical 
dosage that would induce life-threatening intoxication 
(Müller and Bettenay, 1999). Therefore, 8- successive 
doses of ivermectin were administrated to all dogs under 
study. First and second doses were 0.15 mg kg 
-1
 and 0.25 
mg/kg
-1
, respectively. While, remained 6- doses were 0.5 
mg kg
-1
. During this regimen, initial symptoms of 
ivermectin-induced neurological toxicity, as tremor, ataxia, 
apparent blindness and profuse salivations were 
monitored. The efficacy of treatment for rapid recovery from 
canine demodicosis was assessed depending on the skin 
lesion score, skin scrapings with determination the total 
number of mites per scraping, egg accounts and 
hematological response before and after treatment by 30, 
60, 90, and 120 days. The owners assigned an informed 
consent form and all the instructions regarding the 
treatment protocol were informed to them. Additional 
therapy other than IVR or AA was not permitted except in 
case of severe flea infestation or/ and significant secondary 
bacterial infection ectoparasiticidal therapy and antibiotics 
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were administrated, respectively as recommended by 
clinical decision and/or results of susceptibility testing. 
 
Skin lesion score 
Skin lesion score between 0 (normal) and 6 (extremely 
severe) for each case was determined according to the 
extent and range of the lesion (erythema, scales, crusts ⁄ 
comedones, papules ⁄ pustules and alopecia). The extent 
and severity of lesion was calculated firstly of each affected 
area, and then the sum of all affected areas was 
determined to produce the final score.  
 
Total mite and egg counts  
Skin scrapings were taken from five sites using blade 
with capillary oozing followed. Then the scraping from each 
animal was labeled with the animal ID, group and body 
region. Next, the total number of mites (adult, larvae ⁄ 
nymphs, egg) was examined under microscope after mixed 
with mineral oil on glass slide and counted separately in 
each scraping. The same-recorded five sites and/or sites of 
new lesions were scraped in each examination on which 
mites were counted. Two consecutive skin scrapings with 
1- month interval with evidence of absence of any life 
stage, indicate parasitological cure 
 
Hematological analysis 
Blood samples were collected from each animal via 
cephalic vein puncture after hair clipping and disinfectant 
the puncture area with ethyl alcohol 70% to perform 
eosinophil counting using an electronic cell counter (MS9; 
Rhône Mérieux, France). The blood collection was 
performed from each dog at 5 occasions; before treatment 
as well as 30, 60, 90, and 120- days post treatment by 
specific drug as earlier descried. 
  
Statistical analysis 
A statistical software program (JMP for windows 
Version 5.1; SAS Institute, Cary, NC, USA) was used for 
data statistical analysis and for calculation the median and 
range of the assessed variable. For the evaluation of 
treatment results, the main effect of drug and time was 
determined using MANOVA repeated measures on 
treatment and time. Moreover, Wilks’ Lambda test was 
selected to evaluate within group interactions and the 
evidence of time group interactions and to indicate the 
statistically significant difference between groups. While, 
one-way ANOVA with Tukey-Kramer HSD post-hoc 
multiple comparison tests were used to identify which 
group was statistically different from the rest. P < 0.05 was 
considered significant. 
 
RESULTS  
Dogs under study were exhibited severe clinical signs 
with high total mite counts. Seventeen dogs (IVR (n = 8), 
and IVR + AA (n = 9)) completed the full length of 
experiment (4- months) as 11- dogs were withdrawn due to 
various causes including relocation (n = 4), lost to follow up 
(n = 3), death due to unrelated causes (n = 2), and two 
dogs were showed hypersensitivity to IVR. Out of 17- dogs 
completed the 4- months trial, two dogs treated with IVR + 
AA combination therapy were achieved the parasitological 
cure. 
 
Clinical response  
The improvement in skin lesions was observed at 30- 
days post treatment in all treated groups. Three months 
later, complete recovery (Walk’s Lambda for drug x time 
interaction, P < 0.0001) was exhibited in IVR- treated dogs 
and IVR combined with AA- treated group (Table 1). The 
results revealed no statistical significant difference (P > 
0.05) in the skin lesion score between both groups through 
the full length of the experiment (Table 1). Additionally, the 
percent of reduction in the mean of skin lesion score didn't 
exhibited statistical significant difference (P > 0.05) 
between both groups at 30, 60, 90, and 120 days post-
treatment (Figure 1).  
 
Total mite counts 
Deep skin scraping in the affected dogs revealed huge 
total mite counts in dogs under study were clarified upon 
enrolment with range 300–850 (Table 2). Non-significant 
differences (p > 0.05) were observed in the total number of 
mites between groups prior treatment administration (Table 
2). Four months’ post treatment, the mite counts were 
statistically significantly reduced (MANOVA, P < 0.0001; 
Walk’s Lambda for drug x time interaction, P < 0.0001) in 
all treated dogs compared to those at outset (Table 2). 
Interestingly, the mite counts were statistically significantly 
reduced (p < 0.05) in dogs received treatment by 
combination therapy than dogs treated by ivermectin alone 
at one and two- months post treatment (Table 2). 
Moreover, statistical significant difference (P < 0.05) in the 
percent of reduction in the mean of total mite counts 
between both groups was observed at 30 days post-
treatment (50 % for IVR vs 88% for IVR+AA). In contrary, 
no statistical significant difference (P > 0.05) was observed 
between both groups at 60 days (93 % for IVR vs 96 % for 
IVR+AA), 90 days (97.25 % for IVR vs 98.49 % for 
IVR+AA), and 120 days (99.21 % for IVR vs 99.65 % for 
IVR+AA), post-treatment (Figure 1).  
 
Total egg counts 
The mean egg counts in treated dogs were ranged 
from 10 to 49 at initiation (Table 3). Before drug 
administration, the egg counts weren’t exhibited significant 
differences (p > 0.05) between treated dogs (Table 3). One 
month later, significant reduction (p < 0.05) the egg counts 
were observed in all treated groups (Walk’s Lambda for 
drug x time interaction, P < 0.0001) (Table 3). The effect of 
IVR alone or combined with AA was similar on the 
reduction of egg counts (Table 3). Of note, the egg counts 
were statistically significantly reduced (p < 0.05) in dogs 
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received treatment by combination therapy than dogs 
treated by ivermectin alone at one- month post treatment 
(Table 3). Additionally, the percent of reduction in the mean 
egg counts exhibited a statistical significant difference (P < 
0.05) between both treated groups was at 30 days’ post-
treatment (89 % for IVR vs 95.55 % for IVR+AA). In 
contrary, no such statistical significant difference (P > 0.05) 
wasn’t observed between both groups at 60 days, 90 days, 
and 120 days, post-treatment (Figure 1).  
 
Eosinophil counts 
Dogs with juvenile generalized demodicosis exhibited 
significant elevation (P < 0.05) in the eosinophil counts in 
comparison with the control group (Table 4).  From one 
month after IVR administration either alone or combined 
with AA, a significant reduction (MANOVA fit, P < 0.0001, 
Wilks, Lambda test for drug x time interaction, P < 0.0001) 
in eosinophil count was observed (Table 4). Interestingly, 
statistical significant difference (P < 0.05) in the percent of 
reduction in the mean of eosinophil counts between both 
groups was observed at 30 days (46.89 % for IVR vs 
61.72% for IVR+AA), 60 days (49.54 % for IVR vs 69% for 
IVR+AA), and 90 days (58.65 % for IVR vs 71.87% for 
IVR+AA) post-treatment. In contrary, no statistical 
significant difference (P > 0.05) was observed between 
both groups at 120 days (67.44% for IVR vs 69.92 % for 
IVR+AA), post-treatment (Figure 1). Taken together, the 
earlier significant reduction (P < 0.05) in the mite counts 
that observed in dogs received ascorbic acid in 
combination with ivermectin, highlights the superiority of 
this cheap and available immunostimulant agent in 
treatment of dogs naturally infected with juvenile 
generalized demodicosis. 
 
 
 
Table 1. Skin lesion score in dogs treated with ivermectin 1% alone (IVR) or ivermectin 1% combined with ascorbic 
acid (IVR + AA) 
Treated groups Time post-treatment (day)
 
* 
 0 30 60 90 120 
IVR (n=8) 60 (40-120)
a
 40 (20-60)
 b
 10 (0-40)
 c
 0 (0-40)
 c
 0 (0-20)
 c
 
IVR + AA (n=9) 70 (40-120)
a
 40 (20-80)
 b
 20 (0-40)
 c
 0 (0-20)
 c
 0 (0-20)
 c
 
*P > 0.05 no statistically significant differences between the skin lesion score in IVR- treated dogs and IVR+AA combination- 
treated dogs either before treatment or at days post treatment. Variables with different superscript letters in the same row are 
significantly different at P < 0.05. The obtained values represent the median and range (minimum and maximum) of dogs in 
each treated group. MANOVA fit, P = 0.12. Wilks, Lambda test for drug x time interaction, P < 0.0001 
 
 
Table 2. Total mite counts in dogs treated with ivermectin 1% alone (IVR) or ivermectin 1% combined with ascorbic 
acid (IVR + AA) 
Treated groups Time post-treatment (day)
 
* 
 0 30 60 90 120 
IVR (n=8) 590 (300-800)
a
 130 (75-170)
 b
 35.5 (23-48)
 bc
 11.5 (9-20)
 c
 4 (1-10)
 c
 
IVR + AA (n=9) 625 (450-850)
a
 71 (60-80)
 b
 15 (10-33)
 c
 10.5 (5-16)
 c
 2 (0-6)
 c
 
*P < 0.05 statistically significant differences between the total mite counts in IVR- treated dogs and IVR+AA combination- 
treated dogs. Variables with different superscript letters in the same row are significantly different at P < 0.05. The obtained 
values represent the median and range (minimum and maximum) of dogs in each treated group. MANOVA fit, P < 0.0001. 
Wilks, Lambda test for drug x time interaction, P < 0.0001 
 
 
Table 3. Egg counts in dogs treated with ivermectin 1% alone (IVR) or ivermectin 1% combined with ascorbic acid 
(IVR + AA) 
Treated groups Time post-treatment (day)
 
* 
 0 30 60 90 120 
IVR (n=8) 33 (18-49)
a
 3 (1-8)
 b
 0.5 (0-3)
 b
 0 (0-2)
 b
 0 (0-0)
 b
 
IVR + AA (n=9) 32.5 (10-45)
a
 0 (0-4)
 b
 0 (0-1)
 b
 0 (0-1)
 b
 0 (0-0)
 b
 
*P < 0.05 statistically significant differences between the egg counts in IVR- treated dogs and IVR+AA combination- treated 
dogs. Variables with different superscript letters in the same row are significantly different at P < 0.05. The obtained values 
represent the median and range (minimum and maximum) of dogs in each treated group. MANOVA fit, P = 0.0115. Wilks, 
Lambda test for drug x time interaction, P < 0.0001 
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Table 4. Eosinophil counts (%) in dogs treated with ivermectin 1% alone (IVR) or ivermectin 1% combined with 
ascorbic acid (IVR + AA) 
Treated groups Time post-treatment (day)
 
* 
 0 30 60 90 120 
IVR (n=8) 9.40 ± 1.89 
a
 5.21 ± 2.09 
b
 4.26 ± 1.54
  b
 3.95 ± 1.28 
b
 3.20 ± 1.31 
b
 
IVR + AA (n=9) 10.40 ± 1.57 
a
 4.13 ± 1.59 
b
 3.40 ± 1.67 
b
 3.00 ± 0.94 
b
 3.21 ± 1.02 
b
 
Healthy dogs (n=10) 4.40 ± 1.64
 a
 3.60 ± 1.57 
a
 3.52 ± 1.26 
a
 3.20 ± 1.03 
a
 4.11 ± 1.59 
a
 
*P < 0.05 statistically significant differences in the eosinophil counts between the diseased dogs and healthy control dogs. 
Variables with different superscript letters in the same row are significantly different at P < 0.05. The obtained values 
represent the mean and standard deviation (SD) of dogs in each group. MANOVA fit, P < 0.0001. Wilks, Lambda test for 
drug x time interaction, P < 0.0001 
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Fig. 1. Reduction percent (± standard deviation) in mean of skin lesion score (clinical response), total mite counts, 
egg counts and eosinophil counts after different periods of treatment by ivermectin alone (IVR) or ivermectin 
combined with ascorbic acid (IVR + AA). (a) 30- days post-treatment. (b) 60- days post-treatment. (c) 90- days post-
treatment. (d) 120- days post-treatment. *Significant differences between IVR and IVR + AA (P < 0.05). 
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DISCUSSION 
Juvenile generalized demodicosis is one of the most 
common form of demodicosis in the field, whereas, 
characterized clinically by presence of casts, crusts, scales, 
erythematous areas and hair losses in affected body region 
(Ravera et al., 2015). One of the few choices licensed for 
treatment of such disease condition is Amitraz (Medleau 
and Willemse, 1995; Hugnet et al., 2001). Although, the 
potential toxicity resulted from its administration and its 
inconstant efficacy, there has been increasing attention in 
the use of the macrocyclic lactones. In this regard, the most 
widely used drug from macrocyclic lactone is ivermectin 
which is administrated at 400–600 μg/kg orally once per 
day till parasitological cure (Mueller, 2004; Mueller et al., 
2012).  
The relation of CanJGD with the deficiency in the 
animal body’s immune status and the hair losses resulted 
from the disease in the affected dogs, encourage us to 
evaluate the efficacy of immunostimulant agent that has a 
great role in collagen synthesis with hair-regrowth (Dhama 
et al., 2015), subsequently as ascorbic acid in the treatment 
of such cases in the present study. Previous studies 
reported the significant role of micronutrients in 
immunomodulation and their impact on treatment of 
immunodeficiency diseases (Mahima et al., 2013, Rahal et 
al., 2014, Dhama et al., 2015). Interestingly, vitamin C is 
one of the most imperative micronutrients that used as 
immunostimulant immunomodulatory agent (Dhama et al., 
2015). Vitamin C exerts its immunomodulatory effect 
through stimulation of innate immune cells, cell mediated 
immunity and humoral immunity (Dhama et al., 2015). 
Taken together, the antioxidant activity of vitamin C and its 
role as cofactors in the cytokine production and regulation 
beside its significant role in immune homeostasis (Hartel et 
al., 2004; Kunisawa and Kiyono, 2013).  
The obtained data in the current study revealed the 
improvement in clinical response with statistical significant 
reduction (P > 0.05) in the total mite, egg, and eosinophil 
counts in all treated dogs. While, the rapid and marked 
reduction in the total mite numbers and eosinophil counts 
were observed in dogs treated with ascorbic acid combined 
with ivermectin. In fact, usage of skin scraping as indicator 
to complete recovery from demodicosis is a matter of 
depate as the life cycle of the mite extends over a period of 
18–24 days and the scraping is performed on a limited area 
of the lesion (Paterson et al., 2009; Mueller et al., 2012). 
Therefore, a single negative skin scarping is not actual 
indication to the complete recovery from mite infestation. 
Subsequently, the complete recovery is achieved based on 
two consecutive negative skin scrapings at a one-month 
interval (Fourie et al., 2013). In the current study, two out of 
nine- dogs (22.22%) and one out of eight- dogs (12.50%) 
treated with IVR+AA and IVR alone, respectively were 
exhibited two successive negative skin scrapings at a one-
month interval after 4- months treatment. Indeed, 
recurrence of canine generalized demodicosis is 
considered one of the main critical problems of this disease 
due to the non-complete removal of mite from the skin of 
affected dogs. Of note, the obtained data in this study 
denote the possible efficacy of ivermectin and ascorbic acid 
combination in overcoming the relapse of demodicosis in 
dogs. Interestingly, recent similar study (Beugnet et al., 
2016) reported the efficacy of anew-developed antiparasitic 
drug; afoxolaner in complete removal of mite from skin of 
treated dogs at day 84 post-treatment. Therefore, other 
studies are required to evaluate the possible synergistic 
effect of ascorbic acid and afoxolaner in complete removal 
of mite from animal skin.  
Administration of ivermectin combined with ascorbic 
acid resulted in 88.62 %, 96.94 %, 98 %, and 99.65 % 
inhibitions in the total mite counts at 30, 60, 90, and 120 
days post-treatment. These results are higher than the 
12.5% inhibition for imidacloprid/ moxidectin on day 84 
(Beugnet et al., 2016), 45%, 64% and 89% inhibition in 
total live adult mite counts for Advocate administrated at 
once per month, 2-weeks, and weekly on day 120 
(Paterson  et al., 2009), 49%, 93% and 95% inhibition in 
total juvenile mite counts for Advocate administrated at 
once per month, 2-weeks, and weekly on day 120 
(Paterson  et al., 2009). In the present study, 
administration of IVR alone causes 99% reduction in the 
total mite counts at 120 days, which was nearly similar to 
those observed in study of (Paterson  et al., 2009), who 
reported 98% and 97% reduction in the total live adult and 
total juvenile mite counts after administration of IVR by 120 
days. The study limitations should be mentioned. However, 
the potential anti-Demodex effect of IVR and AA was 
exhibited in the present study, further studies are required 
to explore the synergistic relation between both hits (IVR 
and AA). Moreover, other studies are warranted to evaluate 
the anti-parasitic efficacy of ascorbic acid in combination 
with other potential anti-Demodex agent. Furthermore, the 
sample size used in the current study was small and the 
treatment period was short, which may not allow obtaining 
a concrete conclusion. Therefore, future studies should 
perform on larger size samples with evaluation the skin 
scrapings every 30 days after the stopping the treatment. 
 
CONCLUSION 
In conclusion, administration of a cheap, 
immunostimulant and immunomodulatory agent as 
ascorbic acid in combination with commonly used anti-
Demodex agent as ivermectin resulted in rapid and marked 
reduction in the total mite and eosinophil counts in treated 
dogs in comparison with administration of ivermectin alone. 
This high level of efficacy offers new perspectives to 
veterinarians for the control of demodicosis. 
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